健世科技-B(9877.HK)今日收涨15.87%,收盘价报7.3港元,创逾一年新高。中信建投研报看好医疗器械行业的自主可控及出海趋势,认为健世科技具备较强的长期出海能力。根据2024年财报,公司亏损大幅收窄至1.78亿元,账面货币资金达7.08亿元,为商业化战役和产品临床试验提供充足支持。分析指出,2025年将是健世科技从研发驱动转向商业化兑现的关键转折点,Ken-Valve产品将进入商业化阶段...
Source Link健世科技-B(9877.HK)今日收涨15.87%,收盘价报7.3港元,创逾一年新高。中信建投研报看好医疗器械行业的自主可控及出海趋势,认为健世科技具备较强的长期出海能力。根据2024年财报,公司亏损大幅收窄至1.78亿元,账面货币资金达7.08亿元,为商业化战役和产品临床试验提供充足支持。分析指出,2025年将是健世科技从研发驱动转向商业化兑现的关键转折点,Ken-Valve产品将进入商业化阶段...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.